GH Research reports breakthrough in depression treatment
DUBLIN - GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company valued at $551.5 million, announced today significant results from its Phase 2b clinical trial for GH001, an ...
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of ...
FierceBiotech1h
Irish biotech's inhaled drug reduces depression in phase 2 trial
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
GH Research announces primary endpoint met in Phase 2b trial of GH001
PLC reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with ...
GH Research stock soars on positive Phase 2b trial results
Dr. Villy Valcheva, CEO of GH Research, expressed optimism about the trial's results, stating, "Today, as we share our unprecedented positive Phase 2b data, we celebrate a significant milestone in our ...
'It changed my life tremendously': P.E.I.'s new ketamine clinic could offer mental health help
A new clinic in Stratford is offering ketamine treatment to help people with mental health conditions.Ketamine has been used ...
St George News22h
'I'm feeling like myself again': Experience groundbreaking depression treatment at Desert Sands Ketamine
The symptoms of mental health disorders and chronic pain affect every facet of life, especially during the dark, cold days of ...